Gina Cranswick

Medicine & Life Sciences

1. Stroke 100%
2. Chronic Progressive Multiple Sclerosis 93%
3. Randomized Controlled Trials 73%
4. Riluzole 66%
5. Compression Stockings 66%
6. Thigh 54%
7. Amiloride 54%
8. Venous Thrombosis 53%
9. Fluoxetine 52%
10. Neuroprotective Agents 50%
11. Placebos 46%
12. Enteral Nutrition 45%
13. Random Allocation 36%
14. Controlled Clinical Trials 24%
15. Knee 22%
16. Malnutrition 21%
17. Multicenter Studies 19%
18. Brain 19%
19. Venous Thromboembolism 18%
20. Multiple Sclerosis 18%
21. Diet 15%
22. Physicians 14%
23. Scotland 13%
24. Gastrostomy 12%
25. Confidence Intervals 11%
26. Drug Repositioning 11%
27. Guidelines 10%
28. Neurosciences 10%
29. Therapeutics 10%
30. Atrophy 9%
31. Survival 9%
32. Serotonin Uptake Inhibitors 8%
33. Acid Sensing Ion Channels 8%
34. Pharmaceutical Preparations 8%
35. Magnetic Resonance Imaging 8%
36. Clinical Trials 7%
37. Excitatory Amino Acid Antagonists 7%
38. Sample Size 7%
39. Numbers Needed To Treat 6%
40. Cerebrospinal Fluid 6%
41. Popliteal Vein 6%
42. Disease Progression 6%
43. Research Ethics Committees 5%
44. Ethics 5%
45. England 5%
46. Femoral Vein 5%
47. Neuroimaging 5%
48. Proportional Hazards Models 5%
49. Optical Coherence Tomography 5%